172 related articles for article (PubMed ID: 22126805)
1. Dramatic reversal of lymphocytic interstitial pneumonitis in Sjögren's syndrome with rituximab.
Swartz MA; Vivino FB
J Clin Rheumatol; 2011 Dec; 17(8):454. PubMed ID: 22126805
[No Abstract] [Full Text] [Related]
2. Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjögren's syndrome.
Ogasawara H; Sekiya M; Murashima A; Hishikawa T; Tokano Y; Sekigawa I; Iida N; Hashimoto H; Hirose S
Clin Rheumatol; 1998; 17(2):160-2. PubMed ID: 9641517
[TBL] [Abstract][Full Text] [Related]
3. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
Atzeni F; Sarzi-Puttini P
Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
[No Abstract] [Full Text] [Related]
4. Rituximab and lupus interstitial lung disease: friend or foe?
Efthimiou P; Kukar M; Hersh A
Int J Rheum Dis; 2011 Feb; 14(1):e3-4. PubMed ID: 21303472
[No Abstract] [Full Text] [Related]
5. Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study.
Chen MH; Chen CK; Chou HP; Chen MH; Tsai CY; Chang DM
Clin Exp Rheumatol; 2016; 34(6):1077-1084. PubMed ID: 27607895
[TBL] [Abstract][Full Text] [Related]
6. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
Uraoka Y; Tanigawa T; Watanabe K; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Arakawa T
Am J Gastroenterol; 2012 Aug; 107(8):1266-8. PubMed ID: 22859008
[No Abstract] [Full Text] [Related]
7. Efficacy of retreatment with rituximab in patients with primary Sjögren's syndrome.
Meiners PM; Arends S; Meijer JM; Moerman RV; Spijkervet FK; Vissink A; Bootsma H
Clin Exp Rheumatol; 2015; 33(3):443-4. PubMed ID: 25897541
[No Abstract] [Full Text] [Related]
8. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
Nikiphorou E; Hall FC
Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
[No Abstract] [Full Text] [Related]
9. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome.
Brown S; Navarro Coy N; Pitzalis C; Emery P; Pavitt S; Gray J; Hulme C; Hall F; Busch R; Smith P; Dawson L; Bombardieri M; Wan-Fai N; Pease C; Price E; Sutcliffe N; Woods C; Ruddock S; Everett C; Reynolds C; Skinner E; Poveda-Gallego A; Rout J; Macleod I; Rauz S; Bowman S;
BMC Musculoskelet Disord; 2014 Jan; 15():21. PubMed ID: 24438039
[TBL] [Abstract][Full Text] [Related]
10. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.
Moerman RV; Arends S; Meiners PM; Brouwer E; Spijkervet FK; Kroese FG; Vissink A; Bootsma H
Ann Rheum Dis; 2014 Feb; 73(2):472-4. PubMed ID: 23940214
[No Abstract] [Full Text] [Related]
11. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
Ciccia F; Giardina A; Rizzo A; Guggino G; Cipriani P; Carubbi F; Giacomelli R; Triolo G
Ann Rheum Dis; 2013 May; 72(5):782-3. PubMed ID: 23264342
[No Abstract] [Full Text] [Related]
12. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in primary Sjögren's syndrome: a ten-year journey.
Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
St Clair EW; Levesque MC; Prak ET; Vivino FB; Alappatt CJ; Spychala ME; Wedgwood J; McNamara J; Moser Sivils KL; Fisher L; Cohen P;
Arthritis Rheum; 2013 Apr; 65(4):1097-106. PubMed ID: 23334994
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab.
Ring T; Kallenbach M; Praetorius J; Nielsen S; Melgaard B
Clin Rheumatol; 2006 Nov; 25(6):891-4. PubMed ID: 16283417
[TBL] [Abstract][Full Text] [Related]
16. [Is rituximab a promising treatment for Sjögren's syndrome?].
Devauchelle-Pensec V; Pers JO; Youinou P; Saraux A
Rev Med Interne; 2008 Dec; 29(12):967-70. PubMed ID: 18403066
[No Abstract] [Full Text] [Related]
17. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
Pollard RP; Abdulahad WH; Bootsma H; Meiners PM; Spijkervet FK; Huitema MG; Burgerhof JG; Vissink A; Kroese FG
Ann Rheum Dis; 2013 Dec; 72(12):2048-50. PubMed ID: 23864239
[No Abstract] [Full Text] [Related]
18. Summaries for patients. Does rituximab help patients with primary Sjögren syndrome?
Ann Intern Med; 2014 Feb; 160(4):I-11. PubMed ID: 25006621
[No Abstract] [Full Text] [Related]
19. Does rituximab help patients with primary Sjögren syndrome?
Ann Intern Med; 2014 Feb; 160(4):I-11. PubMed ID: 24727838
[No Abstract] [Full Text] [Related]
20. Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.
Justet A; Ottaviani S; Dieudé P; Taillé C
BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25976199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
